Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.44% | -50.00% | -17.86% | 298.90% | 67.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.44% | -50.00% | -17.86% | 298.90% | 67.38% |
| Cost of Revenue | -218.89% | 19.59% | 3.11% | 9.73% | 80.08% |
| Gross Profit | 248.90% | -30.94% | -12.40% | 46.61% | -81.69% |
| SG&A Expenses | 81.96% | 16.11% | 1.98% | 9.75% | 20.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.82% | 18.47% | 2.75% | 9.74% | 68.28% |
| Operating Income | -24.76% | -25.69% | -8.20% | 24.13% | -68.37% |
| Income Before Tax | -8.52% | -13.91% | 7.94% | 32.18% | -60.47% |
| Income Tax Expenses | -438.13% | -251.76% | 122.24% | 43.37% | 176.19% |
| Earnings from Continuing Operations | -5.61% | -1.81% | 6.55% | 32.00% | -63.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.61% | -1.81% | 6.55% | 32.00% | -63.78% |
| EBIT | -24.76% | -25.69% | -8.20% | 24.13% | -68.37% |
| EBITDA | -25.44% | -25.59% | -8.54% | 25.31% | -70.58% |
| EPS Basic | 35.13% | 41.59% | 45.74% | 52.07% | -14.72% |
| Normalized Basic EPS | 27.70% | 35.81% | 46.54% | 52.20% | -12.40% |
| EPS Diluted | 35.13% | 41.59% | 45.74% | 52.07% | -14.72% |
| Normalized Diluted EPS | 27.70% | 35.81% | 46.54% | 52.20% | -12.40% |
| Average Basic Shares Outstanding | 62.78% | 74.32% | 72.21% | 41.86% | 42.77% |
| Average Diluted Shares Outstanding | 62.78% | 74.32% | 72.21% | 41.86% | 42.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
